Thelansis’s “Prostate Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Prostate cancer is a heterogeneous malignancy arising from the prostate, ranging from localized tumors with indolent behavior to aggressive metastatic disease. Many tumors depend on androgen receptor signaling, making androgen deprivation therapy (ADT) central to advanced-disease treatment. Localized cancer may be managed with surveillance, surgery, or radiotherapy according to tumor risk and patient factors, whereas metastatic disease generally requires systemic therapy. Options include ADT with androgen receptor pathway inhibitors, chemotherapy, radioligand therapy, and selected biomarker-directed treatments. Alterations in homologous recombination repair genes or mismatch repair pathways can identify patients for targeted or immune-based approaches. Progression despite castrate testosterone defines castration-resistant disease, where treatment resistance remains a major challenge. PSMA-directed radioligand therapy is moving into earlier metastatic settings, while research focuses on novel androgen receptor strategies, DNA-damage response inhibitors, and combinations designed to extend survival and preserve quality of life.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Prostate Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Prostate Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.